Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment.

Vickman RE, Broman MM, Lanman NA, Franco OE, Sudyanti PAG, Ni Y, Ji Y, Helfand BT, Petkewicz J, Paterakos MC, Crawford SE, Ratliff TL, Hayward SW.

Prostate. 2019 Nov 25. doi: 10.1002/pros.23929. [Epub ahead of print]

PMID:
31763714
2.

Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment.

Yu H, Shi Z, Lin X, Bao Q, Jia H, Wei J, Helfand BT, Zheng SL, Duggan D, Lu D, Mo Z, Xu J.

Prostate. 2019 Oct 21. doi: 10.1002/pros.23920. [Epub ahead of print]

PMID:
31634418
3.
4.

Editorial Comment.

Xu J, Helfand BT.

J Urol. 2019 Oct 3:10109701JU000060278865879a8. doi: 10.1097/01.JU.0000602788.65879.a8. [Epub ahead of print] No abstract available.

PMID:
31580181
5.

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.

Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MWG, Helderman van den Enden ATJM, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon Y Cajal T, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Rønlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T; IMPACT Study Collaborators, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA.

Eur Urol. 2019 Dec;76(6):831-842. doi: 10.1016/j.eururo.2019.08.019. Epub 2019 Sep 16.

6.

Inherited risk assessment of prostate cancer: it takes three to do it right.

Xu J, Labbate CV, Isaacs WB, Helfand BT.

Prostate Cancer Prostatic Dis. 2019 Aug 15. doi: 10.1038/s41391-019-0165-y. [Epub ahead of print] Review. No abstract available.

PMID:
31417171
7.

A New Brief Clinical Assessment of Lower Urinary Symptoms for Women and Men: LURN SI-10.

Cella D, Smith AR, Griffith JW, Kirkali Z, Flynn KE, Bradley CS, Jelovsek JE, Gillespie BW, Helfand BT, Talaty P, Weinfurt KP; and the LURN Study Group.

J Urol. 2019 Jul 31:101097JU0000000000000465. doi: 10.1097/JU.0000000000000465. [Epub ahead of print]

PMID:
31364922
8.
9.

A new outcome measure for LUTS: Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29) questionnaire.

Cella D, Smith AR, Griffith JW, Flynn KE, Bradley CS, Gillespie BW, Kirkali Z, Talaty P, Jelovsek JE, Helfand BT, Weinfurt KP; LURN Study Group.

Neurourol Urodyn. 2019 Aug;38(6):1751-1759. doi: 10.1002/nau.24067. Epub 2019 Jun 21.

PMID:
31225927
10.

Editorial Comment.

Labbate C, Helfand BT.

J Urol. 2019 Aug;202(2):360. doi: 10.1097/01.JU.0000559825.15469.ef. Epub 2019 Jul 8. No abstract available.

PMID:
31095467
11.

Establishing a common metric for self-reported anxiety in patients with prostate cancer: Linking the Memorial Anxiety Scale for Prostate Cancer with PROMIS Anxiety.

Victorson D, Schalet BD, Kundu S, Helfand BT, Novakovic K, Penedo F, Cella D.

Cancer. 2019 Sep 15;125(18):3249-3258. doi: 10.1002/cncr.32189. Epub 2019 May 15.

PMID:
31090933
12.

Concept and benchmarks for assessing narrow-sense validity of genetic risk score values.

Yu H, Shi Z, Wu Y, Wang CH, Lin X, Perschon C, Isaacs WB, Helfand BT, Lilly Zheng S, Duggan D, Mo Z, Lu D, Xu J.

Prostate. 2019 Jul;79(10):1099-1105. doi: 10.1002/pros.23821. Epub 2019 Apr 29.

PMID:
31037745
13.

Systematic evaluation of cancer-specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts.

Shi Z, Yu H, Wu Y, Lin X, Bao Q, Jia H, Perschon C, Duggan D, Helfand BT, Zheng SL, Xu J.

Cancer Med. 2019 Jun;8(6):3196-3205. doi: 10.1002/cam4.2143. Epub 2019 Apr 9.

14.

Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses.

Siddiqui NY, Helfand BT, Andreev VP, Kowalski JT, Bradley MS, Lai HH, Berger MB, Mueller MG, Bickhaus JA, Packiam VT, Fenner D, Gillispie BW, Kirkali Z; Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN).

J Urol. 2019 Nov;202(5):880-889. doi: 10.1097/JU.0000000000000257. Epub 2019 Oct 9.

PMID:
30925127
15.

A Novel Proteomics Approach to Identify Serum and Urinary Biomarkers and Pathways that Associate with Lower Urinary Tract Symptoms in Men and Women: Pilot Results of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Study.

Helfand BT, Andreev VP, Siddiqui NY, Liu G, Erickson BA, Helmuth ME, Lutgendorf SK, Lai HH, Kirkali Z; LURN Study Group.

Urology. 2019 Jul;129:35-42. doi: 10.1016/j.urology.2019.03.014. Epub 2019 Mar 25.

PMID:
30922973
16.

Editorial Comment.

Helfand BT.

J Urol. 2019 Mar;201(3):494. doi: 10.1097/01.JU.0000553706.28279.84. No abstract available.

PMID:
30759688
17.

AUTHOR REPLY.

Fantus RJ, Helfand BT.

Urology. 2019 Jan;123:124-125. doi: 10.1016/j.urology.2018.06.056. No abstract available.

PMID:
30598201
18.

Germline Genetics of Prostate Cancer: Time to Incorporate Genetics into Early Detection Tools.

Fantus RJ, Helfand BT.

Clin Chem. 2019 Jan;65(1):74-79. doi: 10.1373/clinchem.2018.286658. Epub 2018 Nov 20. Review.

PMID:
30459162
19.

The Association Between Tetrahydrocannabinol and Lower Urinary Tract Symptoms Utilizing the National Health and Nutrition Examination Survey.

Fantus RJ, Riedinger CB, Chang C, Helfand BT.

Urology. 2019 Jan;123:120-125. doi: 10.1016/j.urology.2018.06.054. Epub 2018 Aug 21.

PMID:
30142408
20.

Germline mutations in PPFIBP2 are associated with lethal prostate cancer.

Wu Y, Yu H, Zheng SL, Feng B, Kapron AL, Na R, Boyle JL, Shah S, Shi Z, Ewing CM, Wiley KE, Luo J, Walsh PC, Carter HB, Helfand BT, Cooney KA, Xu J, Isaacs WB.

Prostate. 2018 Dec;78(16):1222-1228. doi: 10.1002/pros.23697. Epub 2018 Jul 24.

PMID:
30043417
21.

Symptom Based Clustering of Women in the LURN Observational Cohort Study.

Andreev VP, Liu G, Yang CC, Smith AR, Helmuth ME, Wiseman JB, Merion RM, Weinfurt KP, Cameron AP, Lai HH, Cella D, Gillespie BW, Helfand BT, Griffith JW, DeLancey JOL, Fraser MO, Clemens JQ, Kirkali Z; LURN Study Group.

J Urol. 2018 Dec;200(6):1323-1331. doi: 10.1016/j.juro.2018.06.068. Epub 2018 Jul 7.

22.

Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.

Helfand BT, Chen H, Fantus RJ, Conran CA, Brendler CB, Zheng SL, Walsh PC, Isaacs WB, Xu J.

Prostate. 2018 Jun 19. doi: 10.1002/pros.23664. [Epub ahead of print]

PMID:
29923209
23.

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.

Bancroft EK, Saya S, Page EC, Myhill K, Thomas S, Pope J, Chamberlain A, Hart R, Glover W, Cook J, Rosario DJ, Helfand BT, Hutten Selkirk C, Davidson R, Longmuir M, Eccles DM, Gadea N, Brewer C, Barwell J, Salinas M, Greenhalgh L, Tischkowitz M, Henderson A, Evans DG, Buys SS; IMPACT Study Steering Committee; IMPACT Collaborators, Eeles RA, Aaronson NK.

BJU Int. 2019 Feb;123(2):284-292. doi: 10.1111/bju.14412. Epub 2018 Jun 22.

24.

Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis.

Na R, Wu Y, Jiang G, Yu H, Lin X, Wang M, Conran CA, Fantus RJ, Zhang N, Liu S, Helfand BT, Zheng SL, Isaacs WB, Ding Q, Shen Z, Xu J.

BJU Int. 2018 Nov;122(5):808-813. doi: 10.1111/bju.14370. Epub 2018 Jun 4.

25.

A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.

Wu Y, Yu H, Zheng SL, Na R, Mamawala M, Landis T, Wiley K, Petkewicz J, Shah S, Shi Z, Novakovic K, McGuire M, Brendler CB, Ding Q, Helfand BT, Carter HB, Cooney KA, Isaacs WB, Xu J.

Prostate. 2018 Jun;78(8):607-615. doi: 10.1002/pros.23505. Epub 2018 Mar 9.

PMID:
29520813
26.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MGEM, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden ATJM, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Mar 20;118(6):e17. doi: 10.1038/bjc.2018.11. Epub 2018 Mar 6.

27.

Prevalence and Characteristics of Urinary Incontinence in a Treatment Seeking Male Prospective Cohort: Results from the LURN Study.

Helfand BT, Smith AR, Lai HH, Yang CC, Gore JL, Erickson BA, Kreder KJ, Cameron AP, Weinfurt KP, Griffith JW, Lentz A, Talaty P, Andreev VP, Kirkali Z; LURN.

J Urol. 2018 Aug;200(2):397-404. doi: 10.1016/j.juro.2018.02.075. Epub 2018 Mar 1.

28.

The Relationship between Sleep Disorders and Lower Urinary Tract Symptoms: Results from the NHANES.

Fantus RJ, Packiam VT, Wang CH, Erickson BA, Helfand BT.

J Urol. 2018 Jul;200(1):161-166. doi: 10.1016/j.juro.2018.01.083. Epub 2018 Mar 27.

PMID:
29408214
29.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4. Erratum in: Br J Cancer. 2018 Mar 06;:.

30.

Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease.

Zhang Q, Helfand BT, Carneiro BA, Qin W, Yang XJ, Lee C, Zhang W, Giles FJ, Cristofanilli M, Kuzel TM.

Eur Urol. 2018 May;73(5):648-652. doi: 10.1016/j.eururo.2017.12.008. Epub 2017 Dec 21. Review.

31.

Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort Study.

Cameron AP, Lewicky-Gaupp C, Smith AR, Helfand BT, Gore JL, Clemens JQ, Yang CC, Siddiqui NY, Lai HH, Griffith JW, Andreev VP, Liu G, Weinfurt K, Amundsen CL, Bradley CS, Kusek JW, Kirkali Z; Symptoms of Lower Urinary Tract Dysfunction Research Network Study Group.

J Urol. 2018 Apr;199(4):1023-1031. doi: 10.1016/j.juro.2017.10.035. Epub 2017 Oct 28.

32.

Reasons for Seeking Clinical Care for Lower Urinary Tract Symptoms: A Mixed Methods Study.

Griffith JW, Messersmith EE, Gillespie BW, Wiseman JB, Flynn KE, Kirkali Z, Kusek JW, Bavendam T, Cella D, Kreder KJ, Nero JJ, Corona ME, Bradley CS, Kenton KS, Helfand BT, Merion RM, Weinfurt KP; LURN Study Group.

J Urol. 2018 Feb;199(2):528-535. doi: 10.1016/j.juro.2017.07.067. Epub 2017 Jul 20.

33.

Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.

Chen H, Na R, Packiam VT, Conran CA, Jiang D, Tao S, Yu H, Lin X, Meng W, Zheng SL, Brendler CB, Helfand BT, Xu J.

Prostate. 2017 Aug;77(11):1179-1186. doi: 10.1002/pros.23369. Epub 2017 Jul 2.

PMID:
28670847
34.

Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China.

Na R, Ye D, Qi J, Liu F, Helfand BT, Brendler CB, Conran CA, Packiam V, Gong J, Wu Y, Zheng SL, Mo Z, Ding Q, Sun Y, Xu J.

Prostate. 2017 Aug;77(11):1221-1229. doi: 10.1002/pros.23382. Epub 2017 Jun 30.

PMID:
28664580
35.

A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).

Na R, Helfand BT, Chen H, Conran CA, Crawford SE, Hayward SW, Tammela TLJ, Hoffman-Bolton J, Zheng SL, Walsh PC, Schleutker J, Platz EA, Isaacs WB, Xu J.

Prostate. 2017 Aug;77(11):1213-1220. doi: 10.1002/pros.23380. Epub 2017 Jun 28.

36.

A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations.

Helfand BT, Conran CA, Xu J, Catalona WJ.

Curr Opin Urol. 2017 Sep;27(5):475-480. doi: 10.1097/MOU.0000000000000418. Review.

37.

Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma.

Tallman JE, Pearce SM, Kuchta K, Helfand BT, Eggener SE.

J Urol. 2017 Nov;198(5):1027-1032. doi: 10.1016/j.juro.2017.05.070. Epub 2017 May 25.

PMID:
28551443
38.
39.

Editorial Comment.

Helfand BT.

J Urol. 2017 Mar;197(3 Pt 1):782. doi: 10.1016/j.juro.2016.09.153. Epub 2016 Dec 16. No abstract available.

PMID:
27992747
40.

Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.

Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, Ewing CM, Zhang L, Novakovic K, Petkewicz J, Gulukota K, Helseth DL Jr, Quinn M, Humphries E, Wiley KE, Isaacs SD, Wu Y, Liu X, Zhang N, Wang CH, Khandekar J, Hulick PJ, Shevrin DH, Cooney KA, Shen Z, Partin AW, Carter HB, Carducci MA, Eisenberger MA, Denmeade SR, McGuire M, Walsh PC, Helfand BT, Brendler CB, Ding Q, Xu J, Isaacs WB.

Eur Urol. 2017 May;71(5):740-747. doi: 10.1016/j.eururo.2016.11.033. Epub 2016 Dec 15.

41.

Editorial Comment.

Helfand BT.

J Urol. 2017 Feb;197(2):341. doi: 10.1016/j.juro.2016.08.131. Epub 2016 Oct 24. No abstract available.

PMID:
27789308
42.

Editorial Comment.

Helfand BT.

J Urol. 2016 Nov;196(5):1491. doi: 10.1016/j.juro.2016.06.096. Epub 2016 Aug 1. No abstract available.

PMID:
27490423
43.

Factors Affecting Quality of Life at Different Intervals After Treatment of Localized Prostate Cancer: Unique Influence of Treatment Decision Making Satisfaction, Personality and Sexual Functioning.

Victorson DE, Schuette S, Schalet BD, Kundu SD, Helfand BT, Novakovic K, Sufrin N, McGuire M, Brendler C.

J Urol. 2016 Nov;196(5):1422-1428. doi: 10.1016/j.juro.2016.05.099. Epub 2016 May 31.

PMID:
27259651
44.

Editorial Comment.

Helfand BT.

J Urol. 2017 Jan;197(1):208-209. doi: 10.1016/j.juro.2016.07.109. Epub 2016 Oct 15. No abstract available.

PMID:
27750056
45.

Urologists' Current Practices in Screening and Treating Men With a Family History of Prostate Cancer.

Rudichuk L, Vogel KJ, Wang CH, Helfand BT, Selkirk CG.

Urology. 2017 Jan;99:180-185. doi: 10.1016/j.urology.2016.07.032. Epub 2016 Sep 16.

PMID:
27645528
46.

Misclassification Errors in Unsupervised Classification Methods. Comparison Based on the Simulation of Targeted Proteomics Data.

Andreev VP, Gillespie BW, Helfand BT, Merion RM.

J Proteomics Bioinform. 2016;Suppl 14. pii: 005. Epub 2016 May 16.

47.

Bladder Pneumatosis From a Catastrophic Vascular Event.

Cooke IJ, Okorji LM, Matulewicz RS, Oberlin DT, Helfand BT.

Urol Case Rep. 2016 Aug 4;8:58-60. doi: 10.1016/j.eucr.2016.07.002. eCollection 2016 Sep.

48.

Clinical validity and utility of genetic risk scores in prostate cancer.

Helfand BT, Kearns J, Conran C, Xu J.

Asian J Androl. 2016 Jul-Aug;18(4):509-14. doi: 10.4103/1008-682X.182981. Review.

49.

Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.

Chen H, Liu X, Brendler CB, Ankerst DP, Leach RJ, Goodman PJ, Lucia MS, Tangen CM, Wang L, Hsu FC, Sun J, Kader AK, Isaacs WB, Helfand BT, Zheng SL, Thompson IM, Platz EA, Xu J.

Prostate. 2016 Sep;76(12):1120-9. doi: 10.1002/pros.23200. Epub 2016 May 16.

50.

Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases.

Na R, Ye D, Qi J, Liu F, Lin X, Helfand BT, Brendler CB, Conran C, Gong J, Wu Y, Gao X, Chen Y, Zheng SL, Mo Z, Ding Q, Sun Y, Xu J.

Asian J Androl. 2016 Jul-Aug;18(4):525-9. doi: 10.4103/1008-682X.179857.

Supplemental Content

Loading ...
Support Center